Ceribell, Inc. (CBLL) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Ceribell, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: Ceribell is a medical technology company developing the Ceribell System, a point-of-care EEG platform using AI to detect seizures and delirium in acute care settings. As of December 31, 2025, the system is deployed in over 600 U.S. hospitals. The company recently received FDA 510(k) clearance for a delirium monitoring solution (December 2025) and FDA Breakthrough Device Designation for an LVO stroke detection solution (January 2026).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $89.1 | $65.4 |
| Gross Profit | $78.3 | $56.8 |
| Gross Margin | 88% | 87% |
| Net Loss | $(53.4) | $(40.5) |
| Operating Cash Flow | $(40.8) | $(35.0) |
| Cash & Marketable Securities | $159.3 | $194.4 |
| Long-Term Debt (Principal) | $20.0 | $20.0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 36% year-over-year, driven by a 34% increase in product revenue (disposable wearables) and a 41% increase in subscription revenue.
- Expense Expansion: Operating expenses rose 42% to $136.7 million. Sales and marketing expenses increased 49% due to headcount growth and commissions. General and administrative expenses increased 31%, partly due to costs associated with becoming a public company and intellectual property enforcement.
- Net Loss Widening: The net loss increased by 32% to $53.4 million, reflecting the significant investment in commercial expansion and R&D.
- Regulatory Milestones: Achieved FDA clearance for delirium monitoring and Breakthrough Device Designation for LVO stroke detection, expanding the addressable market beyond seizures.
Guidance, Outlook, and Risks
Outlook: Management believes current cash and marketable securities ($159.3 million) are sufficient to fund operations for at least the next 12 months. The company plans to continue investing in sales and marketing to drive adoption in the ~6,000 acute care facilities in the U.S. and to expand internationally (CE Mark obtained for Europe).
Key Risks:
- Profitability: The company has a history of net losses and expects to incur additional substantial losses in the foreseeable future.
- Reimbursement: Reliance on third-party payers (Medicare, Medicaid, private insurers) for reimbursement of diagnostic tests using the Ceribell System. Changes in reimbursement policies could materially impact demand.
- Supply Chain: Reliance on contract manufacturers in China and Vietnam exposes the company to trade policy risks, tariffs, and geopolitical instability.
- Intellectual Property: Ongoing patent infringement litigation against Natus Medical Incorporated filed in July 2025.
- Regulatory: Future products require FDA clearance; failure to obtain or maintain clearances would halt commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $159.3 million cash balance against the projected burn rate given the widening net loss.
- Reimbursement Stability: Confirm the status of the New Technology Add-on Payment (NTAP) for the Clarity algorithm and potential reimbursement changes for the new delirium indication.
- Customer Utilization: Assess whether revenue growth is driven by new hospital acquisitions or increased utilization (wearable sales) within existing accounts.
- Legal Proceedings: Monitor the progress and potential costs of the patent infringement lawsuit against Natus Medical.
- Debt Covenants: Review compliance with the Venture Loan and Security Agreement (VLSA) covenants, particularly revenue-based ratios.